The combination of the anti-CTLA4 ipilimumab plus carboplatin and paclitaxel was first evaluated in a randomized phase II study in 130 patients with a new diagnosis of ES-SCLC [18]. The gene discussed is CTLA4; the disease is small cell lung carcinoma.